MGNX - Earnings call transcript Q1 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon.

We will begin the MacroGenics 2024 First Quarter Corporate Progress and Financial Results Conference Call in just a moment. [Operator Instructions] At this point, I will turn the call over to Jim Karrels, Senior Vice President, Chief Financial Officer of MacroGenics.

James Karrels

Thank you, operator. Good afternoon, and welcome to MacroGenics' conference call to discuss our first quarter 2020 financial and operational results.

not a chance outlining press has results, review today's who issued we release anyone had to the these announcements. For this afternoon our is at release available the tab This under macrogenics.com. on Investors website

website, expectations, X discussion listen to to purposes future alert those would with the and of as for Actual statements call Private on be Act the in section You may Factors will discussed filed indicated the the annual, that about constitute results where beginning safe Litigation call XXXX. forward-looking including company's this will approximately also it the days, like today's these a harbor the and include after Risk result prospects via those provision of current statements listeners our conference statements plans webcast that from reports by our Securities hours for XX SEC. completed. I archived of is under of may various quarterly materially differ factors, Reform forward-looking important

addition, representing views should upon forward-looking relied as of be not of today as and In represent views subsequent only date. statements any as our our any

and the obligation if over the the While to some do in forward-looking Executive disclaim call Scott by update applicable of future, Chief required President extent our Officer like even to any turn we to I'd statements we point so to views change, specifically to MacroGenics. at these elect may except Koenig, now law. And Dr.

Scott Koenig

on back II financial afternoon. an I important results. our so, on first today. clinical including Thank everyone let data via before review who call key I to update you, the participating webcast call will conference I'd will provide our But our study Jim. and updates turn do welcome Phase Jim, like programs, me this TAMARACK interim to

James Karrels

Thank XXXX, financial highlight quarter This XX, MacroGenics afternoon, March position. which results financial you, reported the ended for our Scott.

March quarter XX, to million collaborative decrease revenue in total Incyte was XXXX. milestone XXXX, agreements, was the This ended this from of received decrease a including MacroGenics As primarily total for revenue quarter compared $XX.X XX, the ended other XX, XXXX. release March the described in in due March a $XX for from revenue million million to $X.X afternoon, our and ended quarter

and million ended were research expenses XX, Our the ended $XX.X the March compared $XX XX, quarter million development to March for quarter XXXX. XXXX, for

related compensation Our March quarter to expenses selling, compared the were the expense million ended for The $XX.X administrative and $XX.X XX, consulting for ended quarter March fees. and stock-based XX, to million increased was primarily XXXX. general increase XXXX,

$XX.X for to Our million quarter ended March net of loss was XX, for the $XX loss net million XXXX. XX, compared March the ended quarter a XXXX,

into balance marketable December million to Our of XXXX. The in XXXX. anticipate partners securities cash, cash of future million a of terms revenues million prior cash securities as and March balance we our March Finally, cash, cash as anticipated as XXXX, product should equivalents guidance, $XXX.X consistent of $XXX.X runway compared that was XX, addition cash our payments and marketable in of runway, XXXX, to XX, our projected from equivalents provide and XX, and with $XXX.X

ongoing funding back to ongoing and call well the the preclinical to TAMARACK LORIKEET anticipated turn expected clinical Our I'll studies our II expenditures now reflect Phase as requirements as studies. And other Scott. related and

Scott Koenig

Jim. you, Thank

vobramitamab study walk of product from candidates disclosure including with each has We our the I key continue promise, through patients prostate to safety and in believe our of you will great metastatic of proprietary TAMARACK and efficacy pipeline castration-resistant duocarmazine of new data programs, cancer.

immune our family a expression BX-HX. or ADC tumors cytotoxic regulation. broad We take a BX BX-HX across advantage multiple involved of solid designed antigen's vobra designed to Vobra duo cover this so tumor deliver have duo expressing types. member jump is in payload let's of the duocarmazine to today, duocarmycin lots DNA-alkylating to is in. Vobramitamab of to molecules

recently BX-HX has few targeted up the form where are earlier release, patients earnings or an target. The Investor which agents. X.X today's as link mg per the free updated to other TAMARACK provided the cut-off under consent interim taxane to we is X androgen set document know, data of ahead radiographic The not expanded sharing received XXX to rPFS is of the to vobra arms enrolled we original this survival, across receptor As population than will to download the informed the ideal regimen experimental direct primary the slide find have mentioned X, fully no or highlights generated previously our data, XXX of you vobra Slide we you safety all and progression-free although attributes agents arm X that patient in X Events duo. press being never section and with basis in for the believe on in kg Relations and today. per press either of a on weeks the patients an in the counted data set who patients Feel This study's completed the total less X XXX ARAT the we were can study based from X chemotherapy is in thus website of conducted access and or data you control mg the Presentations process. cancer is XX, page release. Flip but an X you note kg of TAMARACK a a receive evaluate are date XXXX, with prior containing mCRPC April or patients endpoint. We patients, study as every designed an of duo

is per slide, several I'll by on dosing are roughly disease mg X.X point measure. kg and measurable, see the cohort balanced there subjective of with a that As despite well patients over whereas arm out status split as exception with ECOG you favors number lesions PSA of cohort. very arms per X kg randomization, valuable this in ECOG XX-XX X broken kg characteristics. in not that slightly mg out X.X the patients can X we've baseline Both was than in X. provides fairly baseline ECOG cohort. Slide Keep the mg the fewer target the and mind this per measurable a

terms study that had of you receptor a In agents versus androgen cohorts. to across having can a have recall to patients close taxane see, And XX-XX the both Also a had targeted prior one. more as split access for entry. was than prior few not, those mCRPC

post-baseline had all On X at the measurement. of Next, at show at X, ml let's Slide patients, subjects for X responses PSA duo dose received baseline least nanograms per PSA we who PSAXX least greater biological a XXX vobra activity. had which review represents and X than

For dosing XX% PSA patients while the greater XX.X% confirmed the than a their cohort, of patients kg per X evaluable a experienced PSA of in reduction reduction. XX had greater XX% XX% mg than

In out their with dosing Happily, XX% a while before commenced. the cohort, aligned experienced well reduction the patients PSA XX.X% expectations greater a PSAXX evaluable XX% X.X had confirmed of per mg generally are kg we the laid reduction. PSA PSAXX in results XX study than than these XX.X% of patients greater

with objective target XX.X% summarized XX responses as complete responses stable plus by XX.X%. patients X X on per in rate the as XX kg control dosing by measurements Slide among disease, of lesion measured or confirmed of summary the mg to baseline X the as partial complete some and partial responses Turning confirmed and disease response the or some and while achieved measured of cohort,

kg the unconfirmed was and of unconfirmed XX.X%. confirmed the CRs the in CRs, XX.X%. Among ORR and unconfirmed cohort, dosing control measurements lesion The target ORR of mg disease XX% PRs, the and With per rate XX ORR X.X was unconfirmed inclusion PRs XX.X%. was the the with baseline inclusion patients with was the

PSA mg waterfall for the review plot Let's Slide shows next. the X per X kg waterfall the plot PSA cohort.

XX% the BX-HX appear It of data BX-HX XX.X% there see, scores based in required the therapy XX of XX greater plot. decrease response. patients as the had not biopsy does XX these or of on a XX.X% of expression patients remained achieving can archival H As that the confirmed a PSA. reducing Also shown cutoff. membrane or PSAXX XX for on on with thresholds these patients PSA you or are

this data. BX-HX At X for biomarker this mg X.X the will kg point, required. Slide the still waterfall not is that implication likely interim per reviewing be diagnostic are cohort. shows plot We the PSA

Here, had a XX XX patients XX with a response. in of patients the XX% greater PSA these or or confirmed PSAXX of decrease achieving XX.X%

XX.X% patients data of patients therapy. on remained As of or cutoff, the XX

disease, X investigator-assessed review tumor cohort, shows which with plots. will of patients XX have the a mg X per I post-baseline size XX, did not On assessment. Slide the Next, kg measurable tumor waterfall

XX.X%, patients tumor X for X.X this all having a kg The disease stable while the earlier, ORR was mentioned with ORR XX.X%. Slide confirmed I response was control for per response the partial disease. shows cohort. mg XX but XX.X%, was unconfirmed group rate either the As or

the confirmed ORR The XX%, XX.X%. assessment. of not ORR with the measurable was rate was post-baseline XX.X%. disease disease, patients was Here tumor have The did a this X for XX group while unconfirmed control

Next, duo Slide for the mCRPC I convey will of response, in X tumor a review the mg the for kg swimmer the which plot per XX of results the setting. vobra interim shows durability cohort. sense will hopefully

XX these cohort, is mg unconfirmed the patients with Here tumor XX% responses, of patients, ORR confirmed the cutoff. unconfirmed of per responses remained as with on had data X of or as shown that is therapy the on XX.X% patients the X data response the patients therapy XX.X%. XX.X% confirmed XX of XX evaluable cutoff. In X were XX, XX.X% of the you or dosing unconfirmed responses, still XX the responses see of objective the the X XX or had unconfirmed ORR kg or the can inclusion XX.X%. X.X on Slide

treatment grade. and study any mg patients point leading TAMARACK Next, I data Grade treatment-emergent XX X.X or of on mg experienced Grade X and or at X safety patients an at Of received parameters XX data or Grade. a and as a had Of a study to which duo vobra fatal by or cohort, who classified kg mg events shows events patients greater per noted cohort. the of XX still Slide X summary X X cases in cohort, study drug the kg, X date. a XX date, adverse X.X related, myocardial XX.X% a infarction, at related the X XX Grade patients a greater dosing of adverse dosing XX, the XX.X% as which Slide kg, occurred XX.X% overall not or of adverse XX to event experienced cardiac mg-per-kg as of or per as acute TEAE XX in review of who discontinuation. to treatment study events X of TEAE initially XX.X% the are X of occurred fatal which the study being few classified patients pneumonitis, duo events not or XXX% X XX cut-off any discontinuation. Also, per interim or investigated XX.X% TEAE of had this dosing in as total as Grade the an out follows: treatment assessed possibly related. XX receive at patients included leading vobra cutoff. I'll as the AE in will X the events was drug and occurred arrest,

mg per patient died. cohort X and a a had dosing X.X subsequently grade on addition, fusion plural In kg

on equal specific In shown treatment-emergent adverse to incidents terms than or those XX% XX. as of with greater Slide events,

of cohort For were dosing and XX.X%, note, X cohort X of palmar-plantar the of There of Grade this cohort Grade incidence or the pleural X asthenia, appetite incidence the of in Grade or X X.X%. nausea mg-per-kg no effusion in X.X%. any X X.X%. X included edema, effusion. peripheral XX.X% events. Grade and TEAEs X in in X Grade cohort, cohort common syndrome was Grade erythrodysesthesia palmar-plantar XX.X%, decreased and Grade X a pleural X.X%. most X decreased incidence nausea, of was this X X.X% this Grade The edema, cohort and the Of of dosing peripheral asthenia, of Grade of of incidence the the of in of Grade this grade of mg-per-kg TEAEs greater Grade any included were dosing was fatigue. pleural cohort and Of syndrome events. Also, in X erythrodysesthesia XX.X% There no X.X this effusion of Grade Also, X X.X% and appetite, of greater with note, X most of common X the Grade

being to equal goal as are As in Slide believe and XXXX saw of data represented at severity effects overwhelmingly are activity cutoff than the butterfly of with very pleased we of of effusion the that off with visually and the either Overall, palmar-plantar with dose TEAEs XX, of the of well success April the onset we achieved manageable. interim these the are limited our with to the the data data or side that are greater the Also, study tolerable laid parameters in cut reducing comparison on we expansion I X both aligned Phase of biological what study. We doses Grade recent of in we the erythrodysesthesia incidence to as X. XX, plot the most study. observed XX% all out in pleural or

X endpoint, either as undertaking of in the or for radiographic to mg initial XXXX. We consider the steps will mCRPC data, survival we evaluate Phase are III per rPFS, study selection primary that the kg. To or X.X dose the prepare initiation including of future of study's end, we potential necessary currently the in progression-free continue a to totality

plan tumor additional of we cancer, lung call, safety, share cutoff. Also, cancer, head expand and on ahead, durability earnings lung in types to cell as prior squamous including carcinoma plan trial the data, being XXXX future we with Looking neck cell the cell enroll evaluated to second of non-small a rPFS to the mentioned half TAMARACK updated on data efficacy and the expect and cancer. based in and our anal small melanoma, patients TAMARACK

other X that molecules BX-HX. target mid-XXXX. Recall, initiate dosing to that have expect these cohorts we clinical additional in We in

first, The novel licensed payload, Synaffix. investigational based SYNtecan is E, topoisomerase inhibitor linker which from ADC MGCXXX a incorporating X we an

readily greater both Our incorporates next. MGCXXX a Fc-optimized and validated linker enoblituzumab, these through that second the recently cancer antibodies potent additional an technology. Association monoclonal ADCs. other walk is hydro BX-HX-directed deruxitecan BX-HX Synaffix' targeted to based molecules MGCXXX molecule or space was to with conjugated on investigational topoisomerase-based the at [indiscernible] Research Cancer was of you antibody. potency payload Annual clinically MGCXXX presented payload I'll shown American in In have studies, combines exatecan preclinical Meeting. data for preclinical a DXd, than utilized

has than toxicology well to shown DXd tested. in dose the our mechanisms less to SN-XX. addition, In payload show levels MGCXXX MGCXXX conducted be tolerated was multidrug-resistant and cynomologous susceptible study all that been monkeys Also, at

complementary development. predictable to in escalation conducive displayed domain the models duo approximate dose vobra The tested, a MGCXXX the proportion the targeting We MGCXXX. variable Phase molecule dose view of pharmacokinetics BX-HX. for initiated We for recently MGCXXX as BX-HX Finally, duo. study of I animal is of in vobra to of indicating a behavior further same sequence targeting MGCXXX approach contained clinical

strategy X valuable potentially with believe our and clinical potential cancers, we tool as or tumor remain the different the our pathway repertoire. vobra an another confident mechanisms or viewing distinct stages having BX-HX agents ultimate inhibitor in action specifically, in used of duo address Topo their More may of enhance therapeutic in combination that be targeting with to one MGCXXX utility. We additional

MRI scan an are to intense evaluating translationally as with optional academic radical XXX molecule study investigator-sponsored CT and patients bone conventional with this a activity prostate preferences. high-risk investigator-sponsored, prior our enoblituzumab given of men is patients and and per II imaging, PSMA study to enoblituzumab, localized and cancer. prostate in randomized in collaborators pretreatment as Phase including neoadjuvant the PET well of up cancer. The prostate prostatectomy biopsy prostate as enrolling Regarding institutional will Eligible undergo HEAT

lymphocytes, to most on We cells, the you expressing designed have tumor which Next, such infiltrating abundant tumor PD-X our dual preferential as tetravalent in x are molecule. CTLA-X PD-X microenvironment. update lorigerlimab, bispecific DART blockade I'll on lorigerlimab CTLA-X

provide and data study. of first treated a in XXX of randomized LORIKEET randomized enrollment study clinical in A mCRPC lorigerlimab current are We the half the combination this in second-line trial primary endpoint docetaxel docetaxel the enrolling II The study LORIKEET of the of XXXX. with clinical Phase be expect completing study versus are year includes X:X to the design planned chemotherapy-naive rPFS. patients alone We study patients. anticipate of update total in to a

enroll dose I/II in and XXXX. additional combination in in escalation X the of duo at patients continue lorigerlimab study tumors. In anticipate solid commencing patients expansion study of indication addition, to in with Phase with a combination mCRPC this vobra advanced we We least in dose

our up, x antitumor dosing the next-generation and CDXXX longer to is syndrome bispecific minimize permitting MGDXXX through Next intermittent that DART CDX half-life. a cytokine incorporates component activity designed release maintaining cytolytic molecule CDX while

escalation study including leukemia to and MGDXXX the study. during has is and ongoing option Gilead that Phase license refractory points decision I in positive predefined myelodysplastic dose patients Phase or Our malignancies, the myeloid I with syndromes. of CDXXX acute hematologic MGDXXX Recall relapsed

of ADC in in cancers, antibody. ADAMX specific In cancer proteins preclinical at carcinoma type is X studies, expressed pancreatic, April. topoisomerase representing lung, projects, the payload over colorectal, treatment. We an incorporating attractive and preclinical ADAMX MGCXXX member and gastric, of Annual MGCXXX and for is In second neck it MGCXXX small genesis family activity the role an that a of presented in terms cholangiocarcinoma. multifunctional tumor antitumor the Synaffix progression novel cancer recently is our Adams and transmembrane preclinical making target data multiple Meeting vivo and in a cell targeting play inhibitor-based demonstrated head linker a AACR models X

is inhibitor preclinical tolerated In mild addition, MGCXXX and solid ocular which as the based option ADAMX tumors. offered of treating a with concern investigation therapeutic tubulin a a study, for results MGCXXX effects dose levels at nonhuman in ADCs. These promising no high reversible side with primate continued was support well toxicity

MGCXXX by for this We the are or currently new anticipating, drug investigational end submitting year. application IND of an

look clinical calls. additional on more To future life-changing the as for MacroGenics believe as to we to forward the and has MGCXXX, to about support financial are development open conclude, molecules molecules call delivering telling vision would additional IND our be We now and future medicines to developing potential expertise resources happy we well you questions. I exploring submission. patients. Beyond cancer of technical these for

Operator

with Tara question Our Instructions] the of first Bancroft TD [Operator line comes from Cowen.

Tara Bancroft

So lots now to cycles But of -- Phase somewhat with here, at look the X these questions it safety, I'm the versus similar abstract. looking extra the I sure. does so

you're it terms abstract referring more Or So how could the different from the what cycles. just on improved that on doses? more looks more what is elaborate as this with in you're with these to seeing quite it like you side? efficacy of safety And median is these X

there? So happened could more you what describe

Scott Koenig

Well, actually, Tara, let me sort of safety. through the go

First the was safety January, than January all, in of since in cutoff. now cut X April, the data and months greater we're

effects we also Phase are I study weeks. patients are XX at study. dramatically these We the doses to And majority patients it I achieved all, I that as on the overwhelmingly we in And XX plot the as X, or second listings compared on clearly or side see of figures, both the of the at Grade were on the effects first the Phase are coming X on the the in data Grade in the has to at type on in now manageable this the the up figures well no on PSA in analysis concerning targeted that figure all of propped -- with we you the mean of and head-to-head a as study. note AEs, if included lesion then butterfly set. And the still did of are We are third Phase a the interim they Phase of look study. new off I, -- you results are TAMARACK smattering number of individuals compared weeks as improved. side exceeding data, were figures TAMARACK prostate X you is of the

to compared For to the compared about the of example, TAMARACK X/X the had in to interruptions. Grade of of in as amount Phase specifically, Xs the and half reductions the I group. X/X we Phase discontinuations half prostate of TAMARACK to and drug X/X of only as X/X I total

I Phase we terms we this wanted we achieving to vis-a-vis we laid accomplished the what have as are So achieve. study, out -- in of have

comparisons we prostate key Furthermore, to some other did studies.

to at For rates in studies. the or number This at our of XX% example, discontinuation X.X other X compares mg. the of mg a XX% well the

was the For the example, a arm in with docetaxel XX.X% was TRIDENT-X DOCE study there in then XX.X%. In was the the ] and similarly, was rate of arm, KEYNOTE-XXX, XX.X%. discontinuation for combo CARD And XX.X%. [ cabazitaxel, it arm pembro

for XXXX, as what discontinuations can So even then was if the Amgen's TRIDENT-X STEAP well experimental in XX%. some arm see, you prostate, Daiichi vis-a-vis I XX%, we in at we're docetaxel KEYNOTE-XXX instance, in look at prostate. you quite we're you there CDX with regard doing targets, Grade by here, then studies if was similarly, to for And X, and And XX% others. seeing XX% the Phase new look it in compare

by side overall, as manageable comfortable activity again, pointed they've very and encouraged to safety believe investigators, the has accumulated date. data and I very extremely both with the that safety So they effects, safety are seen we data with while -- managing out, are patients discussions obviously, the the these more these are

Operator

question Jonathan comes line with Chang the next from Partners. Our Leerink of

Jonathan Chang

or and color trying not to does something abstract. dependency you AEs guess or evolution the the there also this previously a were the they deaths submitted treatment-related? else? I'm profile the can second provide patient reflects question, And understand additional evolution whether I any the tolerability to and better versus on time Is just then

Scott Koenig

Yes. Thanks.

the XX the as at between data of that from we had and the prostate with that was So Phase question and from the again, beginning as weeks. of a January and I I we XX cutoff of we a -- that comparison as cutoff, had January, did of original off of the -- the the patients Tara, as safety January reached looked started data

that a the versus was safety study. that Phase head-to-head the was where point I of So at comparison that of

data to continue the And on I look that was that's as have this X been butterfly of so data before, will have part data data earlier, where safety that's prostate I/II at manageable as accumulated. other agents the with to has I quite a now said that what out But approved more been And -- going other we very data in entire again, limited than well ADCs from over -- cancer. as reiterate, a, the as accumulate. We months I safety pointing greater different now population Phase forward. seen, is as not have

So this -- patient other X unrelated. confounding cases of this cardiac matters that's effect pneumonitis with are being cases being regard a of there. regard deaths, the again, kg further cardiac very with regard associated is to it's with investigated was were summary a later. drug. And a The investigated. a X These now, being With decision not drug And patient investigated have the more pointed per as to to say are to of but -- complicated with death additional and months with at mg occurred so cases out, sort and that medical I the particularly -- the it's the of real-time cause deemed further arrest cohort. that one observations deemed that similarly, in we're than these right death the patient occurrence X.X pleural can we was be time. with don't effusion, of matters What

Operator

line the Citi. from comes of question Yigal next with Nochomovitz Our

Ashiq Mubarack

there you This quite pneumonitis I Grade of help A integrating considering few end, the if for recall from to type in these are that guess the lungs? were BX-HX is steroid can't prophylaxis to expression Ashiq occurred. events, pneumonitis I is Yigal. some signal maybe pneumonitis on prevent a moving had been previously. that a And X Mubarack forward? as you on And observed surprised me.

Scott Koenig

I as Again, indicating, these are being was still investigated.

fact, drug with patient. have to the And still investigation. the have and -- in any we number seen cause in not association here and pneumonitis not large of in the So patients effect under regard is we with that

these raises of the ultimate what pneumonitis. So cause with that of is the patients associated again, questions

findings normal certain Let the no I'm second the had not BX-HX, finish with expression but certain BX-HX question, me in was we finish the lung, not it's sorry, your that normally cynomolgous activation, which seen a may monkey can Clearly, just -- you of lung, toxicology in didn't expression have have lung in of studies. cells I occurrence.

Ashiq Mubarack

Okay.

Got confounding. higher a mean, III? question. are dose, a seems is safety forward the Phase it. I you balanced is but it maybe about It little PSAXX, little but how better know choosing the I dose the maybe lower on the bit seems And into higher at another ORR then like little moving efficacy dose. a Okay. at thinking

So how are thinking about you that?

Scott Koenig

Well, point I is gradation. range we're seeing the optimal evaluate a think that nice have to exactly that what that's dosing we -- correct dose. the believe be will here the picked We

be midyear. And achieve towards disease determined happen so we which to this values will when rPFS expect the later we the rate and values, the control in

data. now, So but doses data right as stay the interim this we usable are developable tuned for that, view both potentially and further going with forward

Operator

of question BTIG. line comes next with Kaveri Pohlman the Our from

Kaveri Pohlman

chemo how saw notable you on versus in safety there? differences look like efficacy patients, the comment pretreated chemo-naive Can and any if you

Scott Koenig

consideration Phase both for not study. you at populations, forward nothing going would was go development say what chemo-naive as Thank and I'm comment this with chemo to regard Kaveri either populations that for I responses. into populations III observed the under to we point in are that question. on that, the And but unexpected the terms overall experience of both And is

Kaveri Pohlman

reduced it. from physicians there Got is grade, the and of dose were level potential regarding to that reduction, feedback doses impact their any you interruption then used And durability? received

Scott Koenig

responses continue part even we've on doses swimmers patients and that the Well, sustained modified had very the and nicely wanted have been on these that we illustrate again, when as to circumstances shown and reduced.

mg patient well. doing quite -- treatment you saw there. over again, had, a in As kg and patients We longer on treated on of as were of mg XX you the weeks was there with that are some kg per reductions dose looked per patients some patients the X.X And X

other So using have or in experiences has they doing so to not dose as any are this with and this interim mitigation chemotherapies, modification, for of responses in example, data. reduction far on very comfortable and led we seen that

Kaveri Pohlman

one. last Any thoughts Got it. no efficacy there between and maybe And correlation on expression? is a That's helpful. BX-HX why

Scott Koenig

did situation this a that We Well, number be linker patients of something the H Phase into out toxin on scores, either. study. to the that of have cells. entry it's the may I had that lower a of responses you even that that's although not effect We pointed expression modest we in threshold you see observing was provide -- where a sufficient BX-HX, if were

that fresh may of here. primal The positive there our actually caveat biopsies. be is, we are these as see And So a you some specimens. do if result course, differences

Operator

the comes line question next of with Stephen Stifel. Our from Willey

Stephen Willey

to whether some with higher procedure is the And Could be are I to and CT. routine patients those the proactively screening of proactively pneumonitis, the I for if of of in observed chest X.X that some of for a rates arm, something events. context it's the dyspnea guess, including that the or in x-ray Just maybe that kind of of as not it? needs curious miscategorized Grade some these plus that pneumonitis I'm this respect via know could for, looked X screening perhaps just was be typically

Scott Koenig

as population. no to patient believe observed a they pointed that a, earlier, as I a their was would that is With part out pneumonitis screening has increased there because, get of rate normally of dyspnea, there protocol in the don't I for this treatment. regard

percentages lot the again, causes of are obviously although a quite comment Although and a workup I full are it's -- here clearly, different on the low. dyspnea, there can't of specific patients

patients. still So additional factors issues, reiterate least the the investigation. clearly, of again, pneumonitis are patients data under of there the to and with to-date And other of -- on cases medical we pneumonitis complicating other at are need other get one information the of I'll just

draw conclusions. any So too to early

Stephen Willey

I'm follow-up is the us And both of you in if of what at -- with sure arms both presentation, the this can these median also not but it's duration provide in in of these point?

Scott Koenig

number you we It what mean these number timeline, and X. we of have know plot of don't was -- I of top now on to was -- exceeded doses the doses the and is, significant and a also my have there time -- patients interval. do -- but The off head, of -- large obviously, XX-week don't saw included number the of is here, these swimmers the time the XX- the

on is So which weekly basis. [indiscernible]

Stephen Willey

guess, trial the those patients And this patients just been know out Do respect patient based lines? I arms lastly, X who I had ARPI" for not with treatment attribute XX you know then on, to between for "stable how allowed months.

Scott Koenig

historical regard I in exposure than of me. -- months, recall, front that was less With But XX% XX% to months of regard. in to without about as have that population, I if specific believe I XX it I in than split terms -- the ARAT percentages greater a of XX don't

Operator

question next line Miller the from of Jon Evercore. Our comes with

Jonathan Miller

that I what looks to that Scott, to question Phase we're saw here. love in look you right per earlier hand more number When than know I at I, but obviously, of would appears XX%, there. And little the update to line you see interruptions, today's grading XX% pulling the interruptions in at with that while, and interesting want be syndrome, response to -- update that an XX% Very foot I you update. exactly this poster, I kg get seeing a discontinuations lower said said what XX% for arm mg better with in bit discontinuations, confirmation. from. I you're looking X.X confirm and the Phase that I

arm I in to You're X.X result XX% seeing the XX% today. mg going the Phase of

to this signals, can the love -- X, they look were, is Phase Phase the that lynchpin got say, as So is therapy characterize point longer is I. in than it better. be them This there docs look, going than when a versus particular let -- they did dosing you on much but this going is place to this I number number better people see comfortable you you'd being would stay are to where where to is tox at

Scott Koenig

Yes.

the So I to again, compare -- apples-to-apples here. want

we data comparison And different so I'm the it prostate were all safety was in I you from abstract, is did to populations. the the cohort. reveal out what a believe comparing previous as pulling

on was discontinuations, severity drug look versus study the time interval know I interruptions. in what I Phase And correct whether at the patients Grades comparison in study So X, do of could Phase from to more least look the at in percentage look and same Xx apples-to-apples said you seeing at the I before what here the from the than The reductions, drug. modest you of we're at in a in I'm of what profiles weeks. I'm -- to seeing anywhere of you best, exposure at data, at TAMARACK. as around there Grade XX dose look Phase of Xx seeing clearly whether those of severity the was. to, greater drug we're ultimate that what I whether prostate exposure absolutely side variations I'm is an specific whether time looking trying and I But you just patients, be some and drug X effect the drug

And as feedback where earlier, past not has I are the TAMARACK number I is study. mean reiterate the I from again, pointed vis-a-vis now in we're out Phase manageable concerning. in we in were investigators will this addition, getting we so the tolerability of of been doses the where And

very feeling And here and in delivering the various I'm swimmers so are showed we drug. the treatment pathway some for on that encouraged still despite of patients And dose the I of right modifications interruption. are this as majority the the on plot and

Jonathan Miller

comps I efficacy therapy the -- median of to All right. looking DCR population? in Can you ORR maybe what line the look cohorts that. prior I are and that for these the -- guess prior what's I see the for at many of then therapy, don't side, lines how on I understand and in would in deck

Scott Koenig

I for which get more whether were where was rate or that. we'll confirmed listened observed the presentation ESMO study. here, therapy. objective back a achieve the certainly of median the XX% And we of that in as was by only back not point in was don't guidance unconfirmed on here, I seeing the final you solid as So have of likely to achieving ORR, -- some terms see exceed we per as XX% you mg was it, to XX% know I we in confirmed confirmed up regard many responses should the -- is of November, X.X criteria the the have XX.X%. X data the no and to are unconfirmed the still Again, confirmed that, going given it it in as than you we're XX.X%. of the patients X. study, as kg these started mean I entry X out, was a this well. The in or the the to we I XXXX approximately of it in are But pointed out, made a lines study, had [indiscernible] but pointed X.X comes on with Daiichi in end on the what And when ended this I ORR we have out, continuous of I if and to not

I continuing So to regard is and doing were data the to we're of and of again, quite But with maturation improvement. what expect what continue think expectations this further the data well as this cut.

Jonathan Miller

of prostate space. other toxins safety might you vobra talk are sense. profile duo overlapping [ an use about and Makes you potential not the combination molecule given Can ] with agents expect in the right. to innocuous that It's of All some obviously see here. in

I'm pneumonitis thinking about instance. effusion, So and pleural for

looking what larger combination you are thereby line therapy programs pursuing that -- for in compared this earlier to mean therapy? combinations other use does potential in are early of and in uses So lines enthusiastically

Scott Koenig

activity tumors as given but to vobra patients, in doses lorigerlimab we shortly for are looking and vobra tumor molecule. well. And define cancer, initiated from orthogonal agents. this be not different mechanisms look the -- the DART in Well, finding And a be studies again, single as at only combination in at in the as to have data today would think we with are I very in prostate with interested commented others go-forward bispecific that as much dose duo already we independently of earlier, able very these expect have where mechanistically, we And at dose and we lorigerlimab, this controlling studies shown of we know, finding we PD-X, as well. looking potential CTLA-X, duo good very combinations combination you believe are I to other late-stage of agent the to explore, very described will addition that we

Operator

question next Darout the Markets. from BMO with line Etzer Capital Our comes of

Etzer Darout

you indicated provide So with into given the to you of could a little that you with still lorigerlimab comment duo you color move more combination expansion given viable that plan of studies a I sort profile that are believe. with if is we've the and dose first half, -- bit program? today? specifically know, sort that in seen Maybe sort where you on vobra wanted could sort the with forward, that lorigerlimab, around of I could of moving And had

Scott Koenig

are moving we for with track Yes, on forward that.

maximize the the at final I dose-finding finding to cohort what activity together of X the of and each when safety think to of we're evaluation the explore. both put doses ideal

enrollment we think the to year of in the good pretty half a be I shape tumor will initiate So in in indication. potentially the second prostate another and

for tuned stay that. So

Operator

with comes question Mamtani from B. next Securities. Mayank Our Riley

Mayank Mamtani

you -- on durability, on based for basis, months to that the data? paradigm present you're you designing III how the rPFS one. on you And sequencing, comment what the year. you think I all based seeing Phase you may next think Scott, this importantly, your STEAPX And think could to in know relative about on maybe see on the expectations PSMA if few When split you you look-forward that, how cycles? So your median next be see in about

Scott Koenig

for had greater obviously, was an out much, XX we again but laid what here rPFS X, X, Right as baseline, Yes. and Thanks Mayank. parameters indicated or very X, of looking the baseline as now, higher. I X

the today we fact the I patients these on that think show that data therapy. that still and are

the rPFS is results, longer-lived reason we but we values meet I will no here. the there ultimately of see think some can't

to have at presented the seeing half year. in would of this is the conference wait we'll So be that to a expectation scientific this results. second The

Mayank Mamtani

analysis quick clarification. that. Got too right kind answer exposed maybe There it. Pluvicto you X weren't do RLT in that And Is study. just any of patients many the could if or to

Scott Koenig

radiotherapy? you say did sorry, I'm

Mayank Mamtani

patient. Yes, Pluvicto exposed RLT or

Scott Koenig

the geographic to the of study on marketing patients a patients there when drug we distribution versus the from ability where have the in majority timing number have or they modest the saw when patients -- the the very of Pluvicto you initiated of as U.S. U.S. And the of true. and where either would were on the of given That's from that have enrollment came occurred, seen Europe. to Western that progressed the Europe the

expect numbers small of we So patients in this study. those

Operator

line from of comes Silvan the JMP Tuerkcan Citizens Our next with question Securities.

Silvan Tuerkcan

at the of be death, adjudication conference we presentation available all, or could medical when of that they not? the out if second the by that in we about time treatment-related the find half? a Would First are get

Scott Koenig

they I getting just in. early would I mean, in ongoing we May as cut here come you we're Obviously, April. in results this as we're so. presume did and data

-- patient working So things the specific the depths. the details and study teams and are very in out evaluating the comorbidities other the have is on to hard expectation that finding contributed may

Silvan Tuerkcan

presumably -- data But between the at right? [indiscernible] is DSMB looking these, cut.

Scott Koenig

Absolutely.

Silvan Tuerkcan

especially ongoing? is maybe could unconfirmed high-dose you not walk those -- as XX%, where as a be the confirmed are it to that there's high arm, they to that? high the -- either the are waterfall yet? if still please could characterize but Do responses And plot are Or the or understand talk then through unconfirmed in fair amount responses the me scanned in with rate me basically, your maybe -- reconcile confirmed, the can majority, XX%, are to why I'm or patients response they but trying -- you in

Scott Koenig

Well, XX if as and least weeks with regard that to and if yes, X X.X patients, -- X very scans, say, there these time you frequency look -- of plots of have every for those that's swimmers have at had therapy the the that the again, they XX I plot, X weeks is patient X at there's scans at if probably majority timing -- on I would look still weeks achieved if the scans X had the so scans. had the -- the were had mean I would

scan, curve, it had -- PR you the until a X at of the with that per was he that that X.X QX, fourth it but X top if for achieved kg mg in as look on a initial confirmed at the So scan they confirmed wasn't the instance, the patient probably weeks, the PR. for first evaluation

are a that bottom longer take scan I it. X time. it number is I to will second confirm have not yet there of the positive patients the here and value have that mean a see So gotten line

Operator

Our Goodwin comes from line the next question of Kelsey Partners. Guggenheim with

Kelsey Goodwin

evaluable color RECIST at I you're additional durability early about Or you thinking the how on the any update? looks could at update swimmer durability patients, with plot given you guess the where just least, there? may land have guess, for I for do any fall provide the

Scott Koenig

I X.X that, given of with it's just the patients per kg say, think for example, And early again, Yes. mg disease. in measurable too are on, the to the majority patients still

slide, treatment. noted is ongoing the as still We have that XX.X% here on

have that treat encouraged feel of that given very even with at patients we this these should again, to number a large an mCRPC. So to able be opportunity we point,

Kelsey Goodwin

evaluable the they And it. guess, -- non-RECIST patients, this... of as plots patients evaluable for representative swimmer well as did the are Got for the I non-RECIST kind

Scott Koenig

this a can But representative give baseline. this general to do was disease you say Again, felt feel for that the et evaluable at I Yes. our with would extended well, with durability, RECIST to disease and that cetera. as regard we is good view bony various patients what to a with we wanted measurable representation that is be

this then promised, at that selective provide in And regard. that we to conferences. we is nothing additional scientific But that data at so time data had the as have we here but at look having we a balance want present same investors can the just is more -- we're

Operator

line Our from next comes with question Lawson Barclays. Peter the of

Peter Lawson

improving these Just if patients characterize reductions possibly of And time -- like? could plots the spider best over or potentially characterize reduction the way that. wondering what if PSAXX kind the could on you -- or you look there's staying are PSA

Scott Koenig

[indiscernible], interval long and be I started say they data, not as sustained they do the the data shown encouraging, had to the individual as interim you we Clearly, spider characterize exceptionally PSAs initial and time is at reductions Phase you we parts forward. but have least give to there time. would similarly a I, see a of in patients Yes. that periods I Again, for responses this Phase are we I period going time that will what PSAXX but will do seem in well say are very long over would of at the the continued

Peter Lawson

higher was lower else going discontinuation dose. Or something the reduction that driven a And PSAXX Got there that in on? rate? Was lower is you. by

Scott Koenig

at not this that those the least anything there particular I over are PSAXX though as look both are the though nice says populations X.X, I think time. numbers I seeing idiosyncratic. the X interpret with ones I confirmed the I similar would don't in on expecting would XX-XX is seem even regard think these, patients I at lower populations. of that a had could think, I size -- reduction, over mean out, increase think regard. that little the spurious it's is these more potentially to just And even just pointed I is that

a So look point. this definitive parameter I a at that difference at don't of as

Peter Lawson

best question, your reductions in mind and what And disease the correlates whether agent rate, ORR or if this control for final or PFS? PSA it's then

Scott Koenig

My disease to sense, and it's rate. going be control PFS our

growth avoiding the previously, important is most out thing pointed lesions here. I As new of

recorded as patient XX% percent, as a PR a or patient it's And obviously, a XX a if stable so reduction if be greater disease. has that, will recorded but has

new are as is data think to continues there we'll mature. I have no to as long see that the again, But lesions, fine. As

Operator

to I'd closing to question-and-answer today's concludes session. back That for remarks. turn like Dr. Koenig the call

Scott Koenig

to you, further Well, soon. we thank completion study the the of a forward TAMARACK everybody, today, for good and questions Have evening. look our on and your other programs up updates following

Operator

call. Thank today's for you concludes This participating. conference

disconnect. may You now

MacroGenics (MGNX) 9 May 242024 Q1 Earnings call transcript